{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:23:25Z","timestamp":1791890605479,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.bbcan.2023.188949","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:13:50Z","timestamp":1688210030000},"page":"188949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Ponatinib: An update on its drug targets, therapeutic potential and safety"],"prefix":"10.1016","volume":"1878","author":[{"given":"Yue","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-ran","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2023.188949_bb0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0010","first-page":"2315","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"381","author":"Kurzrock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","article-title":"Ever-advancing chronic myeloid leukemia treatment","volume":"19","author":"Kimura","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0025","first-page":"18","article-title":"Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase","volume":"2","author":"Bose","year":"2013","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.bbcan.2023.188949_bb0030","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2023.188949_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-319-91439-8_5","article-title":"Ponatinib: a third-generation inhibitor for the treatment of CML","volume":"212","author":"Wehrle","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbcan.2023.188949_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nbt0114-9a","article-title":"FDA halts then allows sales of Ariad\u2019s leukemia medication","volume":"32","author":"Senior","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2013.284531","article-title":"The accelerated approval of oncologic drugs lessons from ponatinib","volume":"311","author":"Prasad","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2023.188949_bb0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/17474086.2016.1232163","article-title":"Ponatinib in the therapy of chronic myeloid leukemia","volume":"9","author":"Poch Martell","year":"2016","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0060","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive Leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2018.06.035","article-title":"LC-ESI-MS\/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites","volume":"485","author":"Attwa","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbcan.2023.188949_bb0070","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.21873\/anticanres.14215","article-title":"ABL1-directed inhibitors for CML: efficacy, resistance and future perspectives","volume":"40","author":"Massimino","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0075","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2015-11-681171","article-title":"Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases","volume":"127","author":"Dasgupta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0080","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.bbcan.2023.188949_bb0085","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2023.188949_bb0090","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to Ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2023.188949_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/07391102.2019.1567390","article-title":"How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study","volume":"38","author":"Zhang","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbcan.2023.188949_bb0100","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0105","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3324\/haematol.2017.176347","article-title":"BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib","volume":"103","author":"Byrgazov","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2023.188949_bb0110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jmb.2008.10.067","article-title":"Mapping of DDR1 distribution and oligomerization on the cell surface by FRET microscopy","volume":"385","author":"Mihai","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10059-010-0080-5","article-title":"Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases","volume":"29","author":"Bae","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2023.188949_bb0120","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2023.188949_bb0125","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/ncomms8877","article-title":"Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase","volume":"6","author":"Klein","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.130","article-title":"A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis","volume":"6","author":"Fauster","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2023.188949_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/molecules23020453","article-title":"Identification of novel protein kinase receptor type 2 inhibitors using pharmacophore and structure-based virtual screening","volume":"23","author":"Cruz","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2023.188949_bb0140","doi-asserted-by":"crossref","first-page":"19793","DOI":"10.1038\/s41598-022-23218-5","article-title":"New C3H KitN824K\/WT cancer mouse model develops late-onset malignant mammary tumors with high penetrance","volume":"12","author":"Klein-Rodewald","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2023.188949_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0160","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/092986711794088308","article-title":"Development of RET kinase inhibitors for targeted cancer therapy","volume":"18","author":"Mologni","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbcan.2023.188949_bb0165","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","article-title":"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD","volume":"121","author":"Smith","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0170","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1038\/s41467-020-18123-2","article-title":"Inhibitors of BRAF dimers using an allosteric site","volume":"11","author":"Cotto-Rios","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbrc.2015.06.029","article-title":"Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity","volume":"463","author":"Ahmad","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173868","article-title":"Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells","volume":"895","author":"Kim","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0185","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2012-2672","article-title":"Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer","volume":"98","author":"de Falco","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2023.188949_bb0190","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.apsb.2020.10.024","article-title":"Gene deficiency or pharmacological inhibition of PDCD4-mediated FGR signaling protects against acute kidney injury","volume":"11","author":"Jing","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2023.188949_bb0195","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-13-0397","article-title":"Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing \u03b2-catenin signaling","volume":"13","author":"Jin","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2016.02.017","article-title":"Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2\/vasohibin-1","volume":"148","author":"Kang","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.bbcan.2023.188949_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2015.07.004","article-title":"Ponatinib ameliorates pulmonary fibrosis by suppressing TGF-\u03b21\/Smad3 pathway","volume":"34","author":"Qu","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers10120526","article-title":"Ponatinib inhibits multiple signaling pathways involved in STAT3 signaling and attenuates colorectal tumor growth","volume":"10","author":"Tan","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.188949_bb0215","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13238-018-0533-8","article-title":"Chemical genomics reveals inhibition of breast cancer lung metastasis by ponatinib via c-Jun","volume":"10","author":"Shao","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbcan.2023.188949_bb0220","doi-asserted-by":"crossref","first-page":"1040999","DOI":"10.3389\/fphar.2022.1040999","article-title":"Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0225","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-017-0540-x","article-title":"Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets","volume":"10","author":"Kanojia","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0230","first-page":"2013","article-title":"The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells","volume":"7","author":"Zhang","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0235","doi-asserted-by":"crossref","first-page":"31666","DOI":"10.18632\/oncotarget.15912","article-title":"Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells","volume":"8","author":"Petrilli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2023.188949_bb0240","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-17-0841","article-title":"A high-content screening of anti-cancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy","volume":"17","author":"Sidarovich","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0245","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10637-016-0387-y","article-title":"The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma","volume":"34","author":"Whittle","year":"2016","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2023.188949_bb0250","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/molecules24071363","article-title":"Ponatinib inhibits proliferation and induces apoptosis of liver cancer cells, but its efficacy is compromised by its activation on PDK1\/Akt\/mTOR signaling","volume":"24","author":"Liu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2023.188949_bb0255","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1038\/s41467-020-19555-6","article-title":"MEKK2 mediates aberrant ERK activation in neurofibromatosis type I","volume":"11","author":"Bok","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0260","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddx081","article-title":"PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis","volume":"26","author":"Arts","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbcan.2023.188949_bb0265","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s12885-020-07090-y","article-title":"Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer","volume":"20","author":"Altunel","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2023.188949_bb0270","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12264-019-00437-x","article-title":"Role of elevated thrombospondin-1 in kainic acid-induced status epilepticus","volume":"36","author":"Zhang","year":"2020","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.bbcan.2023.188949_bb0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0280","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.3390\/cancers13235898","article-title":"Receptor-tyrosine kinase inhibitor ponatinib inhibits meningioma growth in vitro and in vivo","volume":"13","author":"Yu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.188949_bb0285","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3389\/fimmu.2019.01393","article-title":"Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0290","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1021\/mp400323c","article-title":"Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML","volume":"10","author":"Miller","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2023.188949_bb0295","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/10428194.2020.1861275","article-title":"In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1-implications for targeted therapy","volume":"62","author":"Heatley","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbcan.2023.188949_bb0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ebiom.2019.11.004","article-title":"CDK4\/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML","volume":"50","author":"Schneeweiss-Gleixner","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2023.188949_bb0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","article-title":"FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib","volume":"36","author":"Gao","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0310","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1078-0432.CCR-19-1606","article-title":"A combinatorial strategy for targeting BRAFV600E-mutant cancers with BRAFV600E inhibitor (PLX4720) and tyrosine kinase inhibitor (ponatinib)","volume":"26","author":"Ghosh","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0315","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1158\/1535-7163.MCT-17-0009","article-title":"Cotargeting of MEK and PDGFR\/STAT3 pathways to treat pancreatic ductal adenocarcinoma","volume":"16","author":"Sahu","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0320","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1535-7163.MCT-14-0258","article-title":"BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2023.188949_bb0325","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/1078-0432.CCR-12-1777","article-title":"Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia","volume":"19","author":"Katagiri","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0330","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ijc.32936","article-title":"Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma","volume":"147","author":"Tee","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2023.188949_bb0335","doi-asserted-by":"crossref","first-page":"53116","DOI":"10.18632\/oncotarget.10605","article-title":"Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells","volume":"7","author":"Okabe","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2023.188949_bb0340","doi-asserted-by":"crossref","first-page":"12643","DOI":"10.1007\/s13277-016-5179-7","article-title":"Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment","volume":"37","author":"Oaxaca","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0345","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1158\/0008-5472.CAN-15-0509","article-title":"Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and hnscc","volume":"75","author":"Singleton","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0350","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/cas.12965","article-title":"Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells","volume":"107","author":"Matsuda","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2023.188949_bb0355","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2021.01.004","article-title":"Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"101","author":"Jimura","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.bbcan.2023.188949_bb0360","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12975-017-0581-z","article-title":"Combination of emricasan with ponatinib synergistically reduces ischemia\/reperfusion injury in rat brain through simultaneous prevention of apoptosis and necroptosis","volume":"9","author":"Tian","year":"2018","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173999","article-title":"Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis","volume":"898","author":"Tu","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0370","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-020-01692-x","article-title":"Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib","volume":"39","author":"Corallo","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0375","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00280-013-2131-z","article-title":"Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models","volume":"71","author":"Gozgit","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0380","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.3390\/jcm11226761","article-title":"Preclinical evaluation of a novel small molecule inhibitor of LIM kinases (LIMK) CEL amide in Philadelphia-chromosome positive (BCR::ABL+) acute lymphoblastic leukemia (ALL)","volume":"11","author":"Berrou","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0385","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.1038\/s41598-022-14114-z","article-title":"Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model","volume":"12","author":"Flietner","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2023.188949_bb0390","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/cancers14112766","article-title":"mTORC1-inhibition potentiating metabolic block by tyrosine kinase inhibitor ponatinib in multiple myeloma","volume":"14","author":"Nazim","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.188949_bb0395","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/1751-7915.13814","article-title":"Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species","volume":"15","author":"Liu","year":"2022","journal-title":"Microb. Biotechnol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115767","article-title":"The ponatinib\/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation\/angiogenesis","volume":"432","author":"El-Lakkany","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0405","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2023.188949_bb0410","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.3390\/cancers14225602","article-title":"Trabectedin is active against two novel, patient-derived solitary fibrous pleural tumor cell lines and synergizes with ponatinib","volume":"14","author":"Ghanim","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.188949_bb0415","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1021\/acs.molpharmaceut.6b00872","article-title":"Codelivery of ponatinib and SAR302503 by active bone-targeted polymeric micelles for the treatment of therapy-resistant chronic myeloid leukemia","volume":"14","author":"Mu","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2023.188949_bb0420","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.nano.2018.08.001","article-title":"Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index","volume":"14","author":"Kallus","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bbcan.2023.188949_bb0425","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1021\/acsabm.0c00685","article-title":"Reproducible and characterized method for ponatinib encapsulation into biomimetic lipid nanoparticles as a platform for multi-tyrosine kinase-targeted therapy","volume":"3","author":"Zinger","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.bbcan.2023.188949_bb0430","doi-asserted-by":"crossref","first-page":"31958","DOI":"10.18632\/oncotarget.24110","article-title":"Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway","volume":"9","author":"Ai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2023.188949_bb0435","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11936-016-0452-z","article-title":"Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options","volume":"18","author":"Brinda","year":"2016","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0440","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","article-title":"A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity","volume":"143","author":"Talbert","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbcan.2023.188949_bb0445","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signaling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0455","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.3390\/ijms22115815","article-title":"Connexin 43 and connexin 26 involvement in the ponatinib-induced cardiomyopathy: sex-related differences in a murine model","volume":"22","author":"Madonna","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2023.188949_bb0460","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbcan.2023.188949_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1501290","article-title":"TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1","volume":"2","author":"Hossain","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2023.188949_bb0470","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"Merkulova","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbcan.2023.188949_bb0475","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm9030820","article-title":"Ponatinib induces vascular toxicity through the notch-1 signaling pathway","volume":"9","author":"Madonna","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbcan.2023.188949_bb0480","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaccao.2022.06.004","article-title":"Involvement of rho-associated coiled-coil containing kinase (ROCK) in BCR-ABL1 tyrosine kinase inhibitor cardiovascular toxicity","volume":"4","author":"Yu","year":"2022","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0485","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2019-02-900472","article-title":"Ponatinib and platelets a conflict in CML","volume":"133","author":"Guilhot","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0490","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0495","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0500","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/ATVBAHA.118.312315","article-title":"Ponatinib combined with rapamycin causes regression of murine venous malformation","volume":"39","author":"Li","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114667","article-title":"Salvianolic acid B and ferulic acid synergistically promote angiogenesis in HUVECs and zebrafish via regulating VEGF signaling","volume":"283","author":"Chen","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0510","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12809\/hkmj187420","article-title":"Rechallenge of ponatinib in chronic myeloid leukemia after hepatotoxicity","volume":"25","author":"Boo","year":"2019","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.bbcan.2023.188949_bb0515","article-title":"BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: an under-recognized phenomenon","volume":"14","author":"Stanchina","year":"2020","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.bbcan.2023.188949_bb0520","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019865704","article-title":"Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors","volume":"9","author":"El-Dabh","year":"2019","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.bbcan.2023.188949_bb0525","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1159\/000517442","article-title":"A case of tyrosine kinase inhibitor-induced bone marrow aplasia that was successfully treated with allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Kamijo","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0530","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1089\/thy.2014.0514","article-title":"Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemia","volume":"25","author":"Palani","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2023.188949_bb0535","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/cup.12326","article-title":"Ponatinib-induced neutrophilic panniculitis","volume":"41","author":"Zhang","year":"2014","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0540","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1080\/09273948.2020.1866618","article-title":"Ponatinib inducing a panuveitis with choroidal effusions and neurosensory retinal detachment in a patient with chronic myeloid leukemia","volume":"30","author":"Patil","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.bbcan.2023.188949_bb0545","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome\u2013negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0550","article-title":"Ponatinib-associated panniculitis: case report and review of the literature","volume":"27","author":"Antwi-Amoabeng","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.bbcan.2023.188949_bb0555","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.jaad.2013.04.061","article-title":"Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib","volume":"69","author":"Jack","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0560","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bbcan.2023.188949_bb0565","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jdcr.2018.07.010","article-title":"Eruptive melanocytic nevi associated with ponatinib","volume":"4","author":"Devred","year":"2018","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.bbcan.2023.188949_bb0570","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520903660","article-title":"A patient with maculopapular rash and lichenoid skin damage caused by ponatinib","volume":"48","author":"Teigen","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bbcan.2023.188949_bb0575","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/ijd.14853","article-title":"Ponatinib-induced lamellar ichthyosis-like eruption","volume":"59","author":"Thakur","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0580","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0585","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.10.002","article-title":"Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel","volume":"120","author":"M\u00fcller","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2023.188949_bb0590","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2023.188949_bb0595","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann. Hematol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:49:56Z","timestamp":1759639796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X23000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0304419X23000987"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.188949","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponatinib: An update on its drug targets, therapeutic potential and safety","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.188949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188949"}}